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ABSTRACT 
Osteoarthritis is a high-incidence painful and debilitating disease characterized by 
progressive degeneration of articular joints, which indicates a breakdown in joint 
homeostasis favoring catabolic processes. Biomechanical loading, associated with 
inflammatory and metabolic imbalances of joint, strongly contributes to the initiation 
and progression of the disease. Obesity is a primary risk factor for disease onset, and 
mechanical factors increased the risk for disease progression. Moreover, inflammatory 
mediators, in particular, adipose tissue-derived cytokines (better known as adipokines) 
play a critical role linking obesity and osteoarthritis. The present article summarizes the 
knowledge about the role of adipokines in cartilage and bone function, highlighting 
their contribution to the imbalance of joint homeostasis and, consequently, pathogenesis 
of osteoarthritis. This article is protected by copyright. All rights reserved 
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INTRODUCTION 
 Osteoarthritis (OA) is a progressive degenerative disease of entire joint 
characterized by molecular (abnormal joint tissue metabolism) anatomic, and/or 
physiologic derangements (characterized by cartilage degradation, bone 
remodeling, osteophyte formation, joint inflammation and loss of normal joint 
function).1,2 It is a major cause of pain and disability in the adult population and 
the most common form of arthritis;3 however, its etiology is largely unknown. In 
fact, OA seems to represent a family of pathologic processes that have a 
common endpoint, but with a multifactorial etiopathogenesis involving genetic, 
molecular and environmental factors, particularly biomechanical stress. 
 Under normal physiological conditions, chondrocytes maintain a 
homeostatic balance between the catabolic and anabolic processes, leading to 
the slow turnover of the cartilage extracellular matrix (ECM). The progressive 
degeneration of cartilage indicates an imbalance in the chondrocyte metabolism 
favoring catabolic processes. Chondrocyte activities are influenced by the 
action of soluble mediators, such as growth factors and cytokines, local matrix 
composition, and biophysical factors, including mechanical (sensed by 
mechanoreceptors) or osmotic stresses.4 Clinical and animal studies 
demonstrated that altered joint loading, either single (acute impact event) or 
repetitive (cumulative contact stress), can lead to alterations in the composition, 
structure, metabolism and mechanical properties of articular cartilage, 
subchondral bone, and other joint tissues, and consequently cause OA.4 Impact 
loads increase cellular activity and tissue hydration and cause remodeling of 
subchondral bone and ECM splitting,5 all characteristics of early stages of OA. 
Joint instability, induced by meniscectomy6 or ligand transection,7 increase 
hydration, collagen disruption and matrix turnover accompanied by a decrease 
in the tissue stiffness in tension, compression, and shear.8–11 Both articular 
cartilage and synovial fluid (SF) from these OA models show an increase of 
biomarkers12 correlated with joint histological damage.13  
 Inflammation also plays an important role in altered loading models of 
OA. It has been reported that, after traumatic injury, the concentrations of pro-
inflammatory cytokines interleukin (IL)-1 and tumor necrosis factor (TNF)-α 
were transiently increased in chondrocytes and articular cartilage.14 Mechanical 
stress-induced nitric oxide (NO), prostaglandin E2 (PGE2) and IL-6 production 
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by chondrocytes,15,16 while fluid shear stress increased proteoglycan synthesis 
in isolated chondrocytes.17,18 Interestingly, chondrocytes embedded in their own 
ECM show similar increases in pro-inflammatory mediators with stress,19,20 but 
not that one's embedded in an agarose matrix,16 which indicates that native 
ECM interactions can influence this response. Mechanical stretch also 
enhances the expression of pro-inflammatory factors in fibroblast-like 
synoviocytes (namely cyclooxygenase (COX)-2, PGE2, and IL-1β),21 and in 
osteoblasts (in particular, IL-6, COX-2, and IL-8).22,23 Moreover, inflammatory 
mediators, such as IL-1β, IL-6, and oncostatin M, affected the osteoblast-
chondrocyte crosstalk.24 Additionally, the administration of nitric oxide synthase 
inhibitors or IL-1 receptor antagonists decreased OA severity in animal 
models.25–27 Altogether, these data evidence that altered biomechanical loading 
is associated with inflammatory and metabolic imbalances of joint that may 
eventually lead to OA pathogenesis.28 
 Obesity, which is associated with a state of low-grade chronic 
inflammation (a state that is also a distinctive feature of osteoarthritis),29 is a 
well-known risk factor for OA incidence, progression, and disability.30 The 
effects of obesity on the joint have been initially attributed to mechanical loading 
and "wear-and-tear" at the surface of cartilage, being bone metabolism also 
affected;31,32 however, there is growing evidence of multifactorial, systemic links 
between obesity and OA.33 A small reduction of 5Kg in body weight was 
associated with an over 50% decrease in the risk of OA,34 and epidemiological 
data showed that the risk of hand OA, a non-weight bearing joint, is about two-
fold in obese people, compared with normal-weight individuals.35 Additionally, 
no significant differences were detected comparing the incidence rates of knee 
OA in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice with 
controls.36 These findings indicated that inflammatory mediators, in particular, 
adipose tissue-derived cytokines (adipokines), play a critical role linking obesity 
and osteoarthritis. Moreover, it has been reported that adipokines are also 
produced by joint tissues and infrapatellar fat pad (IPFP) closely associated to 
the joint. 
 In the present review, we summarized the effects of adipokines, namely 
leptin, adiponectin, visfatin, resistin, and other less-studied adipokines 
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(lipocalin-2, chemerin, and apelin), in cartilage and bone homeostasis and their 
implication in the pathogenesis of osteoarthritis.  
 
LEPTIN 
 Leptin, a 16 kDa non-glycosylated protein encoded by the obese (ob) 
gene,37 is a cytokine-like hormone mainly produced by white adipose tissue 
(WAT). Its levels are positively correlated with the WAT mass and body mass 
index (BMI), but its synthesis is also regulated by inflammatory mediators.38 
This hormone regulates body weight homeostasis through its effects on food 
intake and energy consumption by acting on hypothalamic nuclei, inducing 
anorexigenic factors and suppressing orexigenic neuropeptides.39 Furthermore, 
given the wide pattern of leptin receptor (Ob-R) expression in peripheral tissues, 
leptin is considered a pleiotropic hormone implicated in the control of several 
physiological processes, like lipid homeostasis, insulin secretion, reproductive 
functions, thermogenesis, angiogenesis, or inflammation.38,40,41 
 Obesity is related to an increased risk of OA development and 
progression, primarily due to excessive joint loading.42 However, this positive 
relationship was also verified in non-weigh bearing joints, like hands.35 Linking 
obesity and OA, leptin serum levels were directly correlated with the intensity of 
chronic hand OA pain, but not with hand OA radiographic severity.35,43,44 But, 
further studies are needed to clarify the role of this adipokine in hand OA. Leptin 
levels in SF and its gene expression were significantly correlated with BMI in 
severe OA patients,45 and in severely arthritic cartilage,46 respectively; a 
gender-dependent correlation was described.47 Furthermore, extreme obesity is 
associated with impaired leptin signaling, which induced alterations in the 
subchondral bone without changing systemic inflammatory cytokine levels or 
OA incidence.36,48 Accordingly, leptin-deficient (ob/ob) mice had reduced bone 
mass as well as altered bone microarchitecture (of note, axial and appendicular 
bones may be differentially affected) and consequently, modified bone 
biomechanical properties, with potential effect in bone fracture healing.49–52 
Exogenous leptin administration can act through central nervous system or 
peripherally, inhibiting53 or enhancing54 bone formation, respectively. In 
humans, high leptin levels observed in obesity were thought to be protective to 
bone fracture risk, but leptin resistant conditions and overweight lead to poor 
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bone health outcomes.55 Exercise prevented bone loss and ameliorated bone 
biomechanical properties through regulation of leptin levels, suppression of 
inflammatory factors, and gain of skeletal muscle mass.56,57 
 Thus, leptin has been reported as a key player in the pathogenesis of 
OA. In a study of NEIRID group, it has been shown that expression of leptin 
was higher in the infrapatellar fat pad (IPFP) and synovial fluid (SF) from OA 
patients compared to healthy controls.58 Leptin concentrations in SF exceeded 
those determined in serum,59 indicating a local source of leptin in the joint or 
factors affecting its clearance. In fact, functional Ob-R isoform was detected in 
human adult articular chondrocytes60 and leptin levels were higher in human OA 
chondrocytes than normal chondrocytes.61 Accordingly, the SF leptin levels 
were related with the radiographic severity of OA, suggesting leptin as a 
potential biomarker for quantitative detection of OA.62,63 Interestingly, leptin-
mediated inflammatory processes, thus linking leptin activity with OA 
pathogenesis. Leptin increased the expression of inducible nitric oxide synthase 
(NOS2) alone or in combination with IL-1β, via janus kinase 2 (JAK2), 
phosphoinositide 3-kinase (PI3K) and mitogen-activated kinases (MAP), namely 
MEK1, extracellular signal-regulated kinases (ERK) 1/2, p38, and c-Jun N-
terminal kinases (JNK), in human and murine chondrocytes, as well as in intact 
cartilage.64–67 Nitric oxide mediates the action of IL-1 on joint degradation 
through down-regulation of matrix synthesis and up-regulation of matrix 
metalloproteinase (MMP) activity.68 Induction of COX-2 expression and 
production of PGE2, IL-6, and IL-8 by leptin alone or in combination with IL-1 
was also verified, indicating the role of leptin in enhancing the production of pro-
inflammatory mediators in OA cartilage.64,69 Additionally, leptin can directly 
induce the expression of MMPs, such as MMP-1, MMP-3, and MMP-13 in 
human OA cartilage via activation of nuclear factor (NF)-κB, protein kinase PKC 
and MAP pathways.70 The cartilage-degrading processes could be perpetuated 
by leptin by induction of vascular cell adhesion molecule (VCAM)-1 expression, 
an adhesion molecule responsible for leukocyte and monocyte infiltration at 
inflamed joints.71,72 Altogether, these data highlight the pro-inflammatory and 
catabolic role of leptin on cartilage metabolism. However, leptin also exerts 
anabolic activities in articular cartilage by stimulating the production of growth 
factors, in particular transforming growth factor (TGF)-β and insulin-like growth 
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factor (IGF).45 Leptin could also contribute to dysregulated osteoblast 
differentiation and proliferation in OA by modulation of the levels of alkaline 
phosphatase (ALP), osteocalcin (OC), collagen type I and TGF-β1 (metabolic 
markers in osteoblasts).73,74  
 Altogether, these data indicated that leptin axis is a critical linker between 
obesity and OA by regulating both immune and muscle-skeletal systems.75,76  
 
ADIPONECTIN 
 Adiponectin, also called GBP28, apM1, Acrp30, or AdipoQ, is a 244-
residue protein with structural homology to collagen type VIII and X, and 
complement factor C1q. It is prevalently synthesized by adipose tissue and can 
be found as different molecular forms (trimers, hexamers and also 12-18-
monomer forms). Adiponectin acts specifically via two receptors, AdipoR1 
predominantly found in skeletal muscle and AdipoR2 mainly present in the liver. 
The signal transduction of adiponectin by these receptors involves the activation 
of the AMP-activated kinase (AMPK), peroxisome proliferator-activated receptor 
(PPAR)-α, and PPAR-γ, among other signaling molecules.77,78 Circulating levels 
of adiponectin tend to be low in morbidly obese patients and increase with 
weight loss and thiazolidinediones treatment (PPAR agonists), which enhances 
insulin sensitivity.77,79 It decreases insulin resistance by increasing fatty acid 
oxidation and glucose uptake in the muscle and reducing glucose synthesis in 
the liver.77 Ablation of the adiponectin gene has no dramatic effect in knockout 
mice in a normal diet, but they develop severe insulin resistance and exhibit 
lipid accumulation in muscles when placed on a high-fat/sucrose diet.80 
 Adiponectin has been implicated in the development of OA. Serum and 
plasma levels of adiponectin were significantly increased in OA patients 
compared to healthy controls,81 being higher in erosive OA patients compared 
with non-erosive OA patients,82 as well as in patients with the radiologically 
most severe OA disease.83 No association between adiponectin serum levels 
and radiographic hand OA severity has been verified.43 Moreover, an 
association between adiponectin serum levels, OA biomarkers, and local 
synovial inflammation was observed.83,84 Adiponectin has been detected in OA 
synovial fluids correlating with aggrecan degradation.85 This adipokine could be 
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produced by synovial fibroblasts, IPFP, osteophytes, cartilage and bone tissues 
within the joint.59 In OA cartilage and in human primary chondrocytes, 
adiponectin led to the increased production of NO, IL-6, IL-8, VCAM-1, tissue 
inhibitor of metalloproteinases (TIMP)-1, MMP-1, -3 and -13.69,71,72,83,86 
However, a protective role for adiponectin in the OA pathogenesis was also 
been suggested. This adipokine inhibited IL-1β-induced MMP-13 expression 
and up-regulated TIMP-2 production in human chondrocytes.87 Furthermore, the 
serum adiponectin concentration in a spontaneous animal OA model (STR/Otr 
mice) was lower when compared with control group.88 But, only a few clinical 
data support the protective role of adiponectin against OA.89 These 
contradictory data can be explained by patient heterogeneity and study 
protocols, or different adiponectin significance according to the phase and 
severity of OA. Exercise was associated with increased adiponectin levels 
compared to high-fat-sedentary and control animals, with potential effect in 
preventing bone loss.56 Furthermore, mechanical loading up-regulated 
adiponectin and its receptors in skeletal muscle.90 Adiponectin stimulated 
osteoclast proliferation and mineralization, via p38 MAPK signaling pathway 
and bone morphogenetic protein (BMP)-2,91,92 but contradictory results showed 
inhibition of osteoclast differentiation and promotion of apoptosis.93 Thus, 
adiponectin altered bone metabolism and biomechanical properties;94,95 
however, more studies will be necessary to clarify the exact role of adiponectin 
in the joint cartilage and bone and in the pathogenesis of osteoarthritis. 
 
RESISTIN 
 Resistin, also known as adipocyte-secreted factor (ADSF) or found in 
inflammatory zone 3 (FIZZ3), is a cysteine-rich secretory protein that circulates 
as dimers in human blood.96 Its receptor has not been identified yet, but toll-like 
receptor 4 (TLR4) was suggested to mediate resistin-induced pro-inflammatory 
factors secretion.97 The main source of resistin in rodents is adipocytes,98 while 
in humans is macrophages.99 Thus, non-adipocyte resident inflammatory cells 
are the main resistin source in human adipose tissue.100 In fact, the resistin 
levels in serum increased with obesity (associated with adipose tissue 
inflammation).101 Additionally, resistin was proposed to link obesity and 
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diabetes.96 Resistin promoted insulin resistance in animal models96 via 
suppressor of cytokine signaling (SOCS)-3,102 being this effect less clear in 
humans.103 Interestingly, resistin downregulates AMPK activation in skeletal 
muscle, liver and adipose tissue.104,105 Resistin also plays significant roles in 
autoimmune diseases, nonalcoholic fatty liver disease, cardiovascular diseases, 
and bone metabolism.106,107  
 Resistin stimulated osteoblast proliferation and its expression is 
augmented during osteoclast differentiation, through protein kinase C (PKC) 
and protein kinase A (PKA) signaling pathways.108 In chondrocytes, resistin up-
regulated several cytokines and chemokines (TNF-α, IL-6, and IL-12), through 
NF-κB and CCAAT/enhancer-binding protein (C/EBP)β.109 Moreover, low shear 
stress modulated resistin-induced COX-2 expression in human OA 
chondrocytes110 via NF-κB, cAMP response element binding protein (CREB), 
AMPK and SIRT1, indicating the interplay between mechanical shear stress 
and resistin activity.110 Mechanical stretch also regulated the resistin expression 
in vascular smooth muscle cells111 and cardiomyocytes.112 
  Resistin is augmented in serum and SF after traumatic joint injuries,113 
as well as in OA patients versus healthy controls with no signs of radiological 
OA.84 But, the association between resistin and cartilage or radiographic 
damage is not clear. Some studies have shown that this adipokine was not 
associated with cartilage damage or volume, and hand OA progression,35,43,84 
while another study suggests a positive correlation between resistin and 
radiographic damage in OA patients.114 It was also demonstrated that resistin 
levels were augmented in SF from OA patients, being correlated with resistin 
released from OA cartilage.115 Of note, SF resistin positively correlates with IL-
6, MMP-1 and MMP-3 levels in SF.116 Given the pro-inflammatory profile of 
resistin together with its association with obesity and its effects on bone 
metabolism and chondrocytes activity, this adipokine might be another potential 
linker between obesity, inflammation, and OA.94  
 
VISFATIN 
 Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting 
enzyme in the biosynthetic pathway of nicotinamide adenine dinucleotide (NAD) 
by conversion of nicotinamide into nicotinamide mononucleotide. NAMPT is a 
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52 kDa protein firstly identified as pre-B-cell colony-enhancing factor (PBEF), a 
cytokine-like protein that induced early B-cell maturation in the presence of IL-
17 and stem cell factor117 and inhibits the apoptosis of neutrophils.118 NAMPT is 
a homodimeric protein which functions as both an intracellular form (iNAMPT) 
and an extracellular form (eNAMPT).  
 It has been reported that circulating levels of visfatin were increased in 
metabolic diseases and in inflammation, although its role is still a matter of 
intense debate.119,120 Leukocytes from obese patients, mostly granulocytes, and 
monocytes, produce higher amounts of visfatin when compared with lean 
subjects.121,122 Adipose tissue-derived macrophages have also been described 
as a source of visfatin production.123 In models of acute injury and sepsis, the 
expression of visfatin is up-regulated, being its synthesis controlled by 
glucocorticoids, TNF-α, IL-6 and growth hormone.118 Moreover, visfatin has 
been described to induce the chemotaxis and the production of IL-1β, TNF-α, 
and IL-6 in lymphocytes.124 Accordingly, Busso and colleagues reported a 
functional link between NAD metabolism and inflammation, suggesting the 
potential contribution of NAD-dependent enzymes in the regulation of pro-
inflammatory cytokine production.125 Besides its involvement in inflammation, 
visfatin is up-regulated by mechanical stress via reduction of DNA methylation 
levels and activation of the mechanical stress-inducible region in the visfatin 
promoter, in pulmonary artery endothelial cells;126,127 however, at our 
knowledge, the effect of mechanical loading in visfatin expression at the joint 
tissues is unknown. 
 At cartilage level, visfatin increased the production of PGE2, MMPs, and 
a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), 
which suggests a pro-destructive role of this adipokine.128 In fact, clinical data 
revealed that serum and SF levels of visfatin were higher in OA patients, which 
are correlated with degradation of collagen type II (CTX-II) and aggrecans 
(AGG1 and AGG2).129,130 NAD levels were associated with the increase of 
visfatin levels during osteogenic differentiation.131 Visfatin also stimulated the 
osteoblasts proliferation,132 and induced IL-6 and monocyte chemotactic protein 
1 (MCP)-1 expression in osteoblasts.106 Additionally, different joint structures, 
namely IPFP, synovium, and osteophytes, contributed to the local production of 
visfatin in OA.130  
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 Altogether, these data suggested that visfatin exerts inflammatory and 
catabolic functions at cartilage level and it can play an important role in OA 
pathophysiology.  
OTHER ADIPOKINES 
Lipocalin-2 
 Lipocalin-2 (LCN2), also named siderocalin, 24p3, uterocalin or 
neutrophil gelatinase-associated lipocalin (NGAL), is a glycoprotein originally 
identified in mouse kidney cells and human neutrophil granules,133,134 although 
WAT was thought to be the main source.135 LCN2 circulates as a 25 kDa 
monomer, a 46 kDa homodimer and in a covalent complex with MMP-9.136,137 
The members of lipocalin family contain a hydrophobic ligand binding pocket, 
which confers the ability to bind and transport steroids, lipopolysaccharides 
(LPS), fatty acids, iron, and in the case of NGAL, siderophores.138,139 Besides its 
role in transport small lipophilic molecules, LCN2 has been involved in the 
induction of apoptosis in hematopoietic cells,140 modulation of inflammation141 
and metabolic homeostasis.142 LCN2 expression is elevated in obesity, which 
can be reversed by treatment with thiazolidinediones.143 Furthermore, LCN2 
concentrations in plasma have been associated with several metabolic and 
inflammatory parameters.142–145 The pro-inflammatory transcription factor NF-κB 
has been shown to transactivate LCN2 expression, indicating that this adipokine 
might be involved in inflammatory responses.146 However, the detailed role of 
LCN2 in obesity-associated pathologies has not been fully elucidated so far. 
 LCN2 is expressed in joint tissues,147–149 being a mechano-responsive 
adipokine whose expression is induced by inflammatory mediators. In 
osteoblasts, the absence of mechanical loading induced LCN2 expression, 
which seems to contribute to bone metabolism via stimulation of pro-
osteoclastogenic factors, receptor activator of nuclear factor kappa-B ligand 
(RANKL) and IL-6, and inhibition of anti-osteoclastogenic factor 
osteoprotegerin.150 Accordingly, LCN2 levels have been correlated with an 
increased fracture risk in aged individuals151 and with bone 
microenvironment.152 Inflammatory factors TNF-α and IL-17 also increased 
LCN2 in osteoblasts.153 Moreover, in chondrocytes, the LCN2 expression is 
induced by stimulated osteoblast conditioned medium,74 IL-1β, adipokines 
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(leptin and adiponectin), LPS and dexamethasone.147,154 Interestingly, NO is 
able to exert a control on LCN2 expression in chondrocytes, suggesting the 
existence of a feedback loop regulating its expression.155 Furthermore, LCN2 
levels were increased in OA synovial fluid148,149,156 and OA cartilage.156 LCN2 is 
involved in cartilage degradative processes by blocking MMP-9 auto-
degradation74,148 and by reducing chondrocyte proliferation.157 Furthermore, it 
was reported that LCN2 expression is induced by glucocorticoids alone or in 
combination with IL-1, through corticoids receptors and PI3K, ERK1/2 and 
JAK2.158 The transcription factors E74-like factor 3 (ELF3) and NF-κB were 
reported as modulators of LCN2 expression.159 
 Therefore, LCN2 acts as a sensor of mechanical load and inflammatory 
status of the joint, leading to alterations in subchondral bone, cartilage and 
bone-cartilage crosstalk underlined to OA pathophysiology. 
Chemerin 
 Chemerin, also known as tazarotene-induced gene 2 (TIG2) and retinoic 
acid responder 2 (RARRES2), is a strong chemotactic adipokine that binds to 
the G protein-coupled receptor chemokine-like receptor 1 (CMKLR1 or 
ChemR23).160,161 Two other receptors for this adipokine were described, namely 
CCRL2 and GPR1,162 but their functional significance is largely unknown. 
Chemerin is secreted as an inactive precursor, prochemerin, which is activated 
by proteolytic C-terminal cleavage by neutrophil-derived proteases (elastase 
and cathepsin G), mast cell products (tryptase), proteases of the coagulation 
cascade,163,164 and certain bacterial proteases165 at the inflammatory site. Since 
ChemR23 is expressed primarily by antigen-presenting cells, like dendritic cells 
(DCs), natural killer cells and macrophages, chemerin/ChemR23 signaling 
pathway may serve as a bridge between innate and adaptative immunity.166,167 
Chemerin and its receptor are both expressed in adipose tissue.168 In fact, 
chemerin expression correlates with BMI in humans and obesity, being up-
regulated in adipose tissue of obesity and T2DM sand rats.168–170 This adipokine 
also seems to promote adipocyte differentiation.169 Chemerin is also expressed 
in preosteoblastic cells, having a possible role in osteoblast differentiation.171,172  
Apelin 
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 Apelin is an adipose-secreted cytokine, identified as the ligand for the 
orphan G protein-coupled receptor (GPCR) APJ, also known as the apelin 
receptor.173,174 Apelin is secreted as a 77 amino acid prepropeptide, which is 
then cleaved into various active forms, namely apelin-13, -16, -17, -19 and -36, 
the shorter forms with more potent functionality. A pyroglutamyl form of apelin-
13 also showed a high activity.173 Several evidence suggest that apelin might 
act as a proinflammatory adipokine that contributes to vascular wall 
inflammation.175 Enteric apelin expression is increased by exposure to LPS, IL-6 
or IFN-γ in rodents.176 Furthermore, TNF-α act as a direct regulator of apelin 
expression in human and mouse adipocytes, and intraperitoneal (i.p.) injections 
of TNF-α increased the apelin expression in adipose tissue and enhanced its 
levels in plasma.177 Altogether, these data indicate that apelin may have a 
potential role linking obesity and inflammation. 
 Apelin levels were higher in SF of OA patients compared with healthy 
controls, being positively correlated with the severity of the disease.178 It has 
been demonstrated that apelin can stimulate the chondrocytes’ proliferation and 
increase the expression of catabolic factors, like MMP-1, -3, -9 and IL-1β in 
vitro. Intra-articular injection of apelin up-regulated the expression of MMP-3, -9, 
and IL-1β and decreased collagen II level. Furthermore, apelin injection 
markedly increased ADAMTS-4 and -5 mRNA levels and depleted proteoglycan 
in articular cartilage.178 
 
CONCLUSIONS 
 There is now strong evidence that local and systemic pro-inflammatory 
mediators and cytokines are crucial players in the progressive degeneration of 
joint tissues and development of osteoarthritis. Many studies demonstrated that 
the mechanical stress of the joint (abnormal, altered or injurious loading) 
increases the expression of pro-inflammatory factors by joint cells, which may 
be in part responsible for the catabolic processes that occur in osteoarthritic 
cartilage. But, the precise relationship between biomechanical factors and 
inflammation are not fully understood and additional knowledge would be 
beneficial to understand the onset and progression of osteoarthritis. Obesity, 
one of the primary risk factors for OA, is associated with a state of low-grade 
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chronic inflammation (a cardinal trait that is common also to OA). Significant 
evidence shows that increase of body weight by itself, may not be a risk factor 
for joint degeneration. However, the dysfunction of the abdominal white adipose 
mass together with interactions between joint mechanical overloading and local 
and/or systemic inflammation may prompt the pathogenesis and the 
development of osteoarthritis (Fig. 1). In this context, adipokines are pleiotropic 
molecules synthesized and up-regulated by adipocytes as well as by 
chondrocytes and other cell types from joints (including immune infiltrating cells) 
that play a lead role in promoting and sustaining both inflammatory processes 
as well as ECM degradation. The studies described in this review showed that 
adipokines are crucial factors in the unbalance of joint homeostasis and 
development of osteoarthritis. However, many of the aspects of the adipokine 
network, especially the interplay between inflammatory paths and mechanical 
and metabolic processes in the cartilage and bone disorders remain still 
unclear. Doubtless, further insights into the intimate mechanisms regulating 
peripheral and central adipokines activity might be a great advantage for future 
treatments to osteoarthritis. 
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Figure Legend: 
Figure 1. Fat mass accumulation and dysregulation promote and sustain 
inflammation and ECM degradation in muscle-skeletal system 
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